Author: Michael

Gene therapy company needs to raise additional €10 million to sustain activities to next milestone. GenSight Biologics, a biopharma specializing in gene therapies for retinal neurodegenerative diseases, has announced the successful confirmation of the second Good Manufacturing Practice (GMP) batch of its lead product candidate LUMEVOQ. This event means the French biotech is now eligible to draw down the €4 million second tranche of a bridge financing agreed with Sofinnova Partners, Invus and UPMC Enterprises. GenSight is developing a pipeline of therapies using mitochondrial targeting sequence and optogenetics technologies to address retinal diseases and central nervous system disorders. The company…

Read More